Peringatan Keamanan

Oral, rat: LD50 = >15 gm/kg.

Flucytosine

DB01099

small molecule approved investigational

Deskripsi

A fluorinated cytosine analog that is used as an antifungal agent.

Struktur Molekul 2D

Berat 129.0925
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2.4 to 4.8 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly and virtually completely absorbed following oral administration. Bioavailability 78% to 89%.

Metabolisme

Flucytosine is deaminated, possibly by gut bacteria or by the fungal targets, to 5-fluorouracil, the active metabolite.

Rute Eliminasi

Flucytosine is excreted via the kidneys by means of glomerular filtration without significant tubular reabsorption. A small portion of the dose is excreted in the feces.

Interaksi Obat

1146 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Flucytosine.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Flucytosine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Flucytosine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Flucytosine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Flucytosine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Flucytosine.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Flucytosine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Flucytosine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Flucytosine.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Flucytosine.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Flucytosine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flucytosine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Flucytosine.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Flucytosine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Flucytosine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Flucytosine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Flucytosine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Flucytosine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Flucytosine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flucytosine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Flucytosine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Flucytosine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Flucytosine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Flucytosine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Flucytosine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Flucytosine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Flucytosine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Flucytosine.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Flucytosine.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Flucytosine.
Cladribine Flucytosine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Flucytosine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Flucytosine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Flucytosine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Flucytosine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Flucytosine.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Flucytosine.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Flucytosine.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Flucytosine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Flucytosine.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Flucytosine.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Flucytosine.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Flucytosine.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Flucytosine.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Flucytosine.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Flucytosine.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Flucytosine.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Flucytosine.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Flucytosine.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Flucytosine.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Flucytosine.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Flucytosine.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Flucytosine.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Flucytosine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Flucytosine.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Flucytosine.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Flucytosine.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Flucytosine.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Flucytosine.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Flucytosine.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Flucytosine.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Flucytosine.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Flucytosine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Flucytosine.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Flucytosine.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Flucytosine.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Flucytosine.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Flucytosine.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Flucytosine.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Flucytosine.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Flucytosine.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Flucytosine.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flucytosine.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Flucytosine.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Flucytosine.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Flucytosine.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Flucytosine.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flucytosine.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Flucytosine.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Flucytosine.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Flucytosine.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Flucytosine.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Flucytosine.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Flucytosine.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Flucytosine.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Flucytosine.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Flucytosine.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Flucytosine.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Flucytosine.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Flucytosine.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Flucytosine.
Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Flucytosine.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flucytosine.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Flucytosine.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Flucytosine.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Flucytosine.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Flucytosine.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Flucytosine is combined with Capecitabine.
Trilostane The risk or severity of adverse effects can be increased when Flucytosine is combined with Trilostane.

Target Protein

DNA
Thymidylate synthase TMP1
DNA (cytosine-5)-methyltransferase 1 DNMT1

Referensi & Sumber

Synthesis reference: Bernd Baasner, Erich Klauke, "Process for the preparation of 5-fluorocytosine." U.S. Patent US4703121, issued September, 1961.

Contoh Produk & Brand

Produk: 42 • International brands: 2
Produk
  • Ancobon
    Capsule • 500 mg/1 • Oral • US • Approved
  • Ancobon
    Capsule • 250 mg/1 • Oral • US • Approved
  • Ancobon
    Capsule • 500 mg/1 • Oral • US • Approved
  • Flucytosine
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Flucytosine
    Capsule • 500 mg/1 • Oral • US • Generic • Approved
  • Flucytosine
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Flucytosine
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Flucytosine
    Capsule • 500 mg/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 42 produk.
International Brands
  • Ancotil — Meda
  • Flusine — TTY Biopharm

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul